翰思艾泰正式登陆港交所,市值39亿港元,核心产品HX009正在中国进行三个临床项目

独角兽早知道
Dec 23, 2025

独角兽早知道 iponews|资讯撬动新资本|翰思艾泰-B(03378.HK)今日成功在港交所主板上市,工银国际为独家保荐人。翰思艾泰是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的生物科技公司。自2016年起,集团开发了产品管线,包括一款核心产品及九款其他管线的候选产品,即三款针对肿瘤学的临床阶段候选药物,包括集团的核心产品HX009及主要产品HX301及HX044;及七款临床前...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10